Repurposing of medications for pulmonary arterial hypertension

Mark Toshner*, Edda Spiekerkoetter, Harm Jan Bogaard, Georg Hansmann, Sylvia Nikkho, Kurt W. Prins

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

This manuscript on drug repurposing incorporates the broad experience of members of the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future design of clinical trials in pulmonary hypertension. Drug repurposing, use of a drug in a disease for which it was not originally developed, in pulmonary arterial hypertension has been a remarkable success story, as highlighted by positive large phase 3 clinical trials using epoprostenol, bosentan, iloprost, and sildenafil. Despite the availability of multiple therapies for pulmonary arterial hypertension, mortality rates have modestly changed. Moreover, pulmonary arterial hypertension patients are highly symptomatic and frequently end up on parental therapy and lung transplant waiting lists. Therefore, an unmet need for new treatments exists and drug repurposing may be an important avenue to address this problem.

Original languageEnglish
Pages (from-to)1-12
JournalPulmonary Circulation
Volume10
Issue number4
DOIs
Publication statusPublished - 2020

Cite this